Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor

European Journal of Pharmacology
M OjimaK Nishikawa


The mechanisms of the insurmountable antagonism of 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]1H-benzimid azole -7-carboxylic acid, candesartan (CV-11974), an angiotensin AT1 receptor antagonist, on angiotensin II-induced rabbit aortic contraction were examined in contraction and binding studies. Preincubation of the rabbit aorta with CV-11974 (0.1 nM) for 30 min reduced the maximal contractile response to angiostensin II by approximately 50%. This insurmountable antagonism of CV-11974 was reversed in the presence of losartan (1 microM), a surmountable angiotensin AT1 receptor antagonist. The inhibitory effect of CV-11974 on angiotensin II-induced contraction persisted longer after washing than did that of losartan but was irreversible. Scatchard analysis of [3H]CV-11974 binding in bovine adrenal cortical membranes indicated the existence of a single class of binding sites (Kd = 7.4 nM). Competition binding studies using angiotensin II receptor agonists and antagonists have demonstrated that [3H[CV-11974 binding sites may be identical to angiotensin AT1 receptors. The dissociation rate of [3H]CV-11974 binding (t1/2 = 66 min) was 5 times slower than that of [125I]angiotensin II binding (t1/2 = 12 min). These results ...Continue Reading


Sep 30, 1992·Biochemical and Biophysical Research Communications·Y YamanoT Inagami
Nov 16, 1992·Biochemical and Biophysical Research Communications·A T ChiuW A Roscoe
Jul 31, 1992·Biochemical and Biophysical Research Communications·H YoshidaI Ichikawa
Mar 16, 1992·Biochemical and Biophysical Research Communications·R TakayanagiM Nakamuta
Mar 1, 1992·Medicinal Research Reviews·J V DunciaP B Timmermans
Jan 1, 1990·Journal of Cardiovascular Pharmacology·M de GasparoB Kamber
May 31, 1991·Biochemical and Biophysical Research Communications·A T ChiuP B Timmermans
May 31, 1991·Biochemical and Biophysical Research Communications·N IwaiT Inagami
Nov 15, 1990·Biochemical and Biophysical Research Communications·A T ChiuP B Timmermans
Nov 30, 1989·Biochemical and Biophysical Research Communications·A T ChiuA L Johnson
Aug 30, 1989·Biochemical and Biophysical Research Communications·S WhitebreadM de Gasparo
Sep 5, 1995·European Journal of Pharmacology·N AiyarR M Edwards
Apr 28, 1995·European Journal of Pharmacology·M HaraM Fujimoto
Jun 9, 1995·The Journal of Biological Chemistry·Y YamanoT Hamakubo

❮ Previous
Next ❯


Feb 15, 2012·Naunyn-Schmiedeberg's Archives of Pharmacology·Georges VauquelinPhilip Seeman
Jun 5, 2003·European Journal of Pharmacology·Alexander NapPieter A van Zwieten
Jul 8, 1999·European Journal of Pharmacology·F L FierensG Vauquelin
Apr 3, 1999·British Journal of Pharmacology·M L SmartP J Harris
Jul 28, 2001·European Journal of Clinical Investigation·W KirchJ Schweizer
Feb 7, 2003·Fundamental & Clinical Pharmacology·G VauquelinP M L Vanderheyden
Mar 20, 2010·The Journal of Biological Chemistry·Hamiyet UnalSadashiva S Karnik
Jun 21, 2001·The Journal of Clinical Hypertension·D A Sica
Jun 4, 1999·Journal of Clinical Pharmacology·M M McConnaugheyA J Ingenito
Jan 13, 2004·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Hiroto MatsudaTakao Saruta
Nov 13, 2012·ClinicoEconomics and Outcomes Research : CEOR·Ola GranströmMartin Henriksson
Jan 1, 2010·Integrated Blood Pressure Control·Ikechi G Okpechi, Brian L Rayner
Jul 1, 2006·Future Cardiology·Robert S McKelvie
Jun 23, 2005·Current Medical Research and Opinion·Gerd Bönner, Winfried Fuchs
Jan 3, 2016·Drug Discovery Today. Technologies·Georges VauquelinDavid C Swinney
Mar 1, 2012·Liver International : Official Journal of the International Association for the Study of the Liver·Moon Young KimSei Jin Chang
Jul 9, 2010·Fundamental & Clinical Pharmacology·Marie WennerbergGeorges Vauquelin
Mar 4, 2011·The Journal of Clinical Hypertension·David RussellSverre E Kjeldsen
Jan 19, 2012·Clinical and Experimental Hypertension : CHE·Hiroshi HasegawaIssei Komuro
Feb 8, 2013·Expert Opinion on Drug Metabolism & Toxicology·Fabio AngeliGianpaolo Reboldi
Jul 5, 2005·Expert Opinion on Investigational Drugs·R M EdwardsD P Brooks
Jun 24, 2004·Expert Opinion on Pharmacotherapy·Jan Ostergren
Oct 6, 2006·Expert Opinion on Pharmacotherapy·Robert S McKelvie
Oct 25, 2000·The Journal of Pharmacy and Pharmacology·B FuchsE Mutschler
Nov 4, 2000·Blood Pressure. Supplement·P Meredith
Mar 7, 2018·Organic & Biomolecular Chemistry·Qianqian GuanZhiyong Wang
Mar 29, 2018·Clinical and Experimental Hypertension : CHE·Di ZhaoPingshuan Dong

❮ Previous
Next ❯

Related Concepts

Related Feeds


Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.